- Home
- PSA vs REGN Comparison
PSA vs REGN Comparison
Compare PSA & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSA
- REGN
- Stock Information
- Founded
- PSA 1972
- REGN 1988
- Country
- PSA United States
- REGN United States
- Employees
- PSA N/A
- REGN N/A
- Industry
- PSA Real Estate Investment Trusts
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- PSA Real Estate
- REGN Health Care
- Exchange
- PSA Nasdaq
- REGN Nasdaq
- Market Cap
- PSA 51.9B
- REGN 59.5B
- IPO Year
- PSA N/A
- REGN 1991
- Fundamental
- Price
- PSA $296.69
- REGN $571.82
- Analyst Decision
- PSA Buy
- REGN Buy
- Analyst Count
- PSA 13
- REGN 23
- Target Price
- PSA $334.00
- REGN $794.83
- AVG Volume (30 Days)
- PSA 595.3K
- REGN 962.6K
- Earning Date
- PSA 10-29-2025
- REGN 10-30-2025
- Dividend Yield
- PSA 4.11%
- REGN 0.62%
- EPS Growth
- PSA N/A
- REGN 5.03
- EPS
- PSA 9.17
- REGN 39.67
- Revenue
- PSA $4,758,111,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- PSA $1.58
- REGN N/A
- Revenue Next Year
- PSA $3.74
- REGN $4.97
- P/E Ratio
- PSA $31.87
- REGN $14.31
- Revenue Growth
- PSA 2.13
- REGN 5.38
- 52 Week Low
- PSA $256.60
- REGN $476.49
- 52 Week High
- PSA $369.99
- REGN $1,182.31
- Technical
- Relative Strength Index (RSI)
- PSA 60.88
- REGN 51.32
- Support Level
- PSA $287.85
- REGN $559.62
- Resistance Level
- PSA $294.83
- REGN $588.70
- Average True Range (ATR)
- PSA 4.25
- REGN 17.58
- MACD
- PSA 1.00
- REGN -2.28
- Stochastic Oscillator
- PSA 88.56
- REGN 27.31
About PSA Public Storage
Public Storage is the largest owner of self-storage facilities in the US, with more than 3,300 self-storage facilities in 40 states and approximately 245 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage. The company also has a merchandise business, a third-party property management business, and an insurance business that offers products to cover losses for the goods in self-storage facilities.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).